|
Tuesday 4th October 2022 |
Text too small? |
Cannasouth Limited (NZX: CBD ) is pleased to announce that it has received its first shipment of verified cannabis medicines.
Cannasouth CEO Mark Lucas says, “This accomplishment marks the end of a near two-year process since submitting product assessments with the Medicinal Cannabis Agency.
"The differentiated formulations of our products will provide New Zealand patients and prescribers with new treatment options compared to existing products on the New Zealand market. We are confident these products offer patients and prescribers a point of difference to meet the treatment needs of a wider range of conditions.”
Navigating and establishing the supply chain for its first medicines means Cannasouth is now generating revenue from the sale of medicines in New Zealand.
A list of all medicinal cannabis products that meet the New Zealand minimum quality standard can be found here: https://www.health.govt.nz/our-work/regulation-health-and-disability-system/medicinal-cannabis-agency/medicinal-cannabis-agency-information-health-professionals/medicinal-cannabis-products-meet-minimum-quality-standard
-ENDS-
NXZ MAP_First Verified Cannabis Medicines Received
No comments yet
February 20th Morning Report
SCL - Chief Financial Officer Transition
BLS - Strong YTD performance
CEN announces opening of NZ$75 million Retail Offer
AIA - 1H26 Interim Results
February 19th Morning Report
TWL - Share Purchase Plan Results
GMT revaluation, unit buyback and proposed structure update
Devon Funds Morning Note - 17 February 2026
CEN - Contact successfully completes NZ$450m Placement